A practical reference on Ac-SDKP: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-23. Anything still debated is marked as such rather than presented as settled.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
| Property | Value | Notes |
|---|---|---|
| Storage temperature (dry) | -20 °C | Protected from light and moisture |
| Storage temperature (solution) | -80 °C | Single-use aliquots recommended |
| Identity assay | LC-MS or MALDI-TOF | Confirms mass near 889 Da |
| Purity assay | RP-HPLC | Reports main peak percentage |
| Common impurities | Truncated peptides, deamidated forms | Arise from synthesis or storage |
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
is the outside diameter of the tube. The correlation constant C is 0.62 for horizontal cylinders and vertical plates, and 0.67 for spheres. Vapor properties are evaluated at film temperature. For stable film boiling on a horizontal surface, Berenson has modified Bromley's equation to yield,
Cantrell explained the reunion saying, We want to celebrate what we did and the memory of our friend. We have played with some [singers] who can actually bring it and add their own thing to it without being a Layne clone. We're not interested in stepping on [Staley's] rich legacy. It's a tough thing to go through. Do you take the Led Zeppelin approach and never play again, because the guy was that important? That's the approach we've taken for a lot of years. Or, do you give it a shot, try something? We're willing to take a chance on it. It's completely a reunion because the three of us who're left are back together. But it's not about separating and forgetting—it's about remembering and moving on. Before the tour, Kinney mentioned in an interview that he would be interested in writing new material, but not as Alice in Chains. During the VH1 Rock Honors concert honoring Heart on May 12, 2007, Alice in Chains performed Heart's "Barracuda" fronted by country singer Gretchen Wilson. Heart's guitarist Nancy Wilson also joined them onstage. Alice in Chains joined Velvet Revolver for a run of U.S. and Canadian gigs from August through October 2007. During that tour, the band also performed four special acoustic-only shows, named as "The Acoustic Hour". The acoustic performance at The Rave/Eagles Club in Milwaukee, Wisconsin on August 31, 2007, was recorded for an upcoming live album.
Foodborne botulism results from contaminated foodstuffs in which C. botulinum spores have been allowed to germinate and produce botulism toxin, and this typically occurs in canned non-acidic food substances that have not received a strong enough thermal heat treatment. C. botulinum prefers low oxygen environments and is a poor competitor to other bacteria, but its spores are resistant to thermal treatments. When a canned food is sterilized insufficiently, most other bacteria besides the C. botulinum spores are killed, and the spores can germinate and produce botulism toxin. Botulism is a rare but serious paralytic illness, leading to paralysis that typically starts with the muscles of the face and then spreads towards the limbs. The botulinum toxin is extremely dangerous because it cannot be detected by sight or smell, and ingestion of even a small amount of the toxin can be deadly. In severe forms, it leads to paralysis of the breathing muscles and causes respiratory failure. In view of this life-threatening complication, all suspected cases of botulism are treated as medical emergencies, and public health officials are usually involved to prevent further cases from the same source.
== References == Butler, Rohan, MA., Bury, J.P.T., MA., & Lambert M.E., MA., editors, Documents on British Foreign Policy 1919–1939, 1st Series, Her Majesty's Stationery Office, London, 1960, vol. x, Chapter VIII, "The Plebiscites in Allenstein and Marienwerder January 21 – September 29, 1920" Keynes, John Maynard. A Revision of the Treaty: Being a Sequel to The Economic Consequences of the Peace, Harcourt, Brace, 1922 Kossert, Andreas. Masuren: Ostpreussens vergessener Süden, ISBN 3-570-55006-0 (in German) Mayer, S. L., MA. History of the First World War – Plebiscites:Self Determination in Action, Peter Young, MA., editor, BPC Publishing Ltd., UK., 1971. Rhode, Gotthold. Die Ostgebiete des Deutschen Reiches, Holzner-Verlag Würzburg, 1956. Tooley, T. Hunt. National Identity and Weimar Germany: Upper Silesia and the Eastern Border, 1918–1922, U of Nebraska Press, 1997, ISBN 0-8032-4429-0 Topolski, Jerzy. An Outline History of Poland, Interpress, 1986, ISBN 83-223-2118-X Wambaugh, Sarah. Plebiscites since the World War, Washington DC, 1933. I pp 99–141; II pp 48–107 Williamson, David G. The British in Germany 1918–1930, Oxford, 1991, ISBN 0-85496-584-X
Moreover, the apparent effect of PPIs cannot be caused by publication bias, according to a meta-analysis on 49 studies (2009). PPIs studied included producing gratitude letters, performing optimistic thinking, replaying positive life experiences, and socializing with people. Also, in a newer meta-analysis (39 studies, 6,139 participants, 2012), the standardized mean difference was 0.34 higher for subjective well-being, 0.20 for psychological well-being and 0.23 for depression. Three to six months after the intervention, the effects for subjective well-being and psychological well-being were still significant, so effects seem fairly sustainable. However, in high-quality studies, the positive effect was weaker, though positive, so authors considered further high-quality studies necessary to strengthen the evidence. They claimed that the above-mentioned meta-analysis (2009) did not put enough weight on the quality of studies. PPIs found positive included blessings, kindness practices, taking personal goals, and showing gratitude. The interventions called "Gratitude Journaling" and "Three Good Things" seem to operate via gratitude. There is evidence that, when gratitude journaling, focussing on quality over quantity as well as people more than possessions, yields greater benefits. There is also evidence of a diminished effect from gratitude journaling if it is done more than once or twice a week.
Sources: en.wikipedia.org
=== Movement of NAPLs in the saturated zone === In the saturated zone, the spaces between particles are filled with water. As such, a three-phase model of NAPL phase distribution is used in this zone, which excludes the gaseous phase. Once NAPLs reach the water table in the saturated zone, LNAPLs will float while DNAPLs will sink. Both LNAPLs and DNAPLs can remain in the water table for long periods of time, slowly dissolving and forming harmful chemical plumes; for this reason, remediation in the saturated zone is of particular importance to scientists.
The foundation for sequencing proteins was first laid by the work of Frederick Sanger who by 1955 had completed the sequence of all the amino acids in insulin, a small protein secreted by the pancreas. This provided the first conclusive evidence that proteins were chemical entities with a specific molecular pattern rather than a random mixture of material suspended in fluid. Sanger's success in sequencing insulin spurred on x-ray crystallographers, including Watson and Crick, who by now were trying to understand how DNA directed the formation of proteins within a cell. Soon after attending a series of lectures given by Frederick Sanger in October 1954, Crick began developing a theory which argued that the arrangement of nucleotides in DNA determined the sequence of amino acids in proteins, which in turn helped determine the function of a protein. He published this theory in 1958.
=== Gluconeogenesis === Gluconeogenesis is a metabolic pathway consisting of a series of eleven enzyme-catalyzed reactions, resulting in the generation of glucose from non-carbohydrate substrates. The beginning of this process takes place in the mitochondrial matrix, where pyruvate molecules are found. A pyruvate molecule is carboxylated by a pyruvate carboxylase enzyme, activated by a molecule each of ATP and water. This reaction results in the formation of oxaloacetate. NADH reduces oxaloacetate to malate. This transformation is needed to transport the molecule out of the mitochondria. Once in the cytosol, malate is oxidized to oxaloacetate again using NAD+. Then oxaloacetate remains in the cytosol, where the rest of reactions will take place. Oxaloacetate is later decarboxylated and phosphorylated by phosphoenolpyruvate carboxykinase and becomes 2-phosphoenolpyruvate using guanosine triphosphate (GTP) as phosphate source. Glucose is obtained after further downstream processing.
From then on, Suhner ran the business by himself. Studer, on the other hand, went on to found his own company "Willi Studer", known as Studer today and famous for its audio equipment. In 1968, Bertold Suhner resigned from his post in the operational management of Metrohm and became strongly committed to the environment. He even fought for causes that could harm his own company, making it a difficult time for the new managing directors Lorenz Kuhn and Hans Winzeler. As a result of his intransigence in environmental matters, he also alienated friends, leaving him socially isolated towards the end of his life. Since 1982, Metrohm AG has been a full subsidiary of the Metrohm Foundation, which is the only shareholder of Metrohm AG. Metrohm co-founder Bertold Suhner put the foundation in place to ensure independence and thereby maintain the ability to make unswayed decisions. The foundation is not only dedicated to the operation of Metrohm AG, but also to charitable and cultural purposes. For example, in 1999, the Metrohm Foundation equipped the public gymnasium Kantonsschule Trogen in the Swiss town of Trogen with internet access and more than 100 computer workstations to ensure that the public school can keep up with international standards. It has also endowed a professorship for the research on new materials at the Zurich University of Applied Sciences since 2014. Until 2006, 36 subsidiaries had been founded. For the most part, these are situated abroad and form a worldwide support and sales network.
Sources: en.wikipedia.org
== External links == GLUT4+Protein at the U.S. National Library of Medicine Medical Subject Headings (MeSH) USCD—Nature molecule pages: The signaling pathway, "GLUT4"; contains a high-resolution network map. Accessed 25 December 2009.
==== Intracellular trafficking ==== Actin-myosin pairs can also participate in the trafficking of various membrane vesicles and organelles within the cell. Myosin V is activated by binding to various cargo receptors on organelles, and then moves along an actin filament towards the (+) end, pulling its cargo along with it. These nonconventional myosins use ATP hydrolysis to transport cargo, such as vesicles and organelles, in a directed fashion much faster than diffusion. Myosin V walks towards the barbed end of actin filaments, while myosin VI walks toward the pointed end. Most actin filaments are arranged with the barbed end toward the cellular membrane and the pointed end toward the cellular interior. This arrangement allows myosin V to be an effective motor for the export of cargos, and myosin VI to be an effective motor for import.
CNS excitation: nervousness, agitation, anxiety, apprehension, tingling around the mouth (circumoral paraesthesia), headache, hyperesthesia, tremor, dizziness, pupillary changes, psychosis, euphoria, hallucinations, and seizures CNS depression with heavier exposure: drowsiness, lethargy, slurred speech, hypoesthesia, confusion, disorientation, loss of consciousness, respiratory depression, and apnoea. Cardiovascular: hypotension, bradycardia, arrhythmias, flushing, venous insufficiency, increased defibrillator threshold, edema, and/or cardiac arrest – some of which may be due to hypoxemia secondary to respiratory depression. Respiratory: bronchospasm, dyspnea, respiratory depression or arrest Gastrointestinal: metallic taste, nausea, vomiting, agita, and diarrhea Ears: tinnitus Eyes: local burning, conjunctival hyperemia, corneal epithelial changes/ulceration, diplopia, visual changes (opacification) Skin: itching, depigmentation, rash, urticaria, edema, angioedema, bruising, inflammation of the vein at the injection site, irritation of the skin when applied topically Blood: methemoglobinemia Allergy ADRs associated with the use of intravenous lidocaine are similar to the toxic effects of systemic exposure above. These are dose-related and more frequent at high infusion rates (≥3 mg/min). Common ADRs include headache, dizziness, drowsiness, confusion, visual disturbances, tinnitus, tremor, and/or paraesthesia.
== Non-drug inhibitors == Many natural products (including anti-oxidants) that have been promoted to have anti-cancer and anti-inflammatory activity have also been shown to inhibit NF-κB. There is a controversial US patent (US patent 6,410,516) that applies to the discovery and use of agents that can block NF-κB for therapeutic purposes. This patent is involved in several lawsuits, including Ariad v. Lilly. Recent work by Karin, Ben-Neriah and others has highlighted the importance of the connection between NF-κB, inflammation, and cancer, and underscored the value of therapies that regulate the activity of NF-κB. Extracts from a number of herbs and dietary plants are efficient inhibitors of NF-κB activation in vitro. Nobiletin, a flavonoid isolated from citrus peels, has been shown to inhibit the NF-κB signaling pathway in mice. Likewise, various withanolides of Withania somnifera (Ashwagandha) have been found to have inhibiting effects on NF-κB through inhibition of proteasome mediated ubiquitin degradation of IκBα.
The colloidal gold protein assay is a highly sensitive biochemical assay for determining the total concentration of protein in a solution (~0.1 ng/μL to 200 ng/μL). It was first described in 1987 by two groups who used commercially available "Aurodye" colloidal gold solutions. Notably, the formulation of Aurodye changed between 1987 and 1990 such that it became incompatible with protein assays, however vendors such as Bio-Rad & Diversified Biotech starting offering colloidal gold formulations that were suitable for protein assays. These products have since been discontinued and there are no vendors that currently explicitly sell colloidal gold for the assay, however detailed synthetic procedures were published to produce the ~17-40 nm gold nanoparticles that are suitable for the assay, along with modifications to increase the shelf stability of the colloidal gold & adapt the assay to microplate format & increase its sensitivity. Gold nanoparticles in the ~17-40 nm size range that are presumably compatible with the assay are currently commercially available.
Sources: en.wikipedia.org
The dry powder is normally kept at -20 °C, protected from light and moisture. Reconstituted solutions are often divided into aliquots and stored at -80 °C to reduce freeze-thaw damage.
Reverse-phase HPLC assesses purity, and mass spectrometry confirms molecular mass. The combination helps distinguish the target peptide from truncated or modified impurities.
Buffer composition, pH, adsorption to containers, and freeze-thaw history can all affect the amount of intact peptide in solution. These factors may change results even when the starting material is chemically correct.
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.